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Tsoupras and colleagues have postulated, in a recent review in Nutrients, that the key to 
reducing the incidence of cardiovascular disease is to control the activities of inflammatory mediators 
such as platelet-activating factor (PAF) by diet, exercise, and healthy lifestyle choices [1]. We agree 
with this sensible conclusion, which is based on the extensive scientific literature. The authors argue 
that their proposal is contrary to the lipid (or cholesterol) hypothesis. This supposes that the reduction 
of plasma lipid concentrations will reduce new incidents of cardiovascular disease, a concept 
developed over many decades from the recommendation in 1976 that a combined drug/diet regimen 
in a study with large numbers of male hyperlipidemic subjects would be necessary to test the 
accuracy of the hypothesis [2]. Following extensive studies with the statins as lipid-lowering drugs, 
the accumulation of evidence for the lipid hypothesis was then presented in 2006 with Steinberg 
concluding that the controversy was solved by the results of these studies, stating that “The 
cholesterol controversy could have been resolved much earlier if all of us had looked at all of the 
evidence” [3]. However, this conclusion on the lipid hypothesis continues to arouse passionate 
arguments, as shown in the review by Tsoupras and colleagues [1] and in other recent reviews [4]. 
Chronic disease of the cardiovascular system is not just a modern phenomenon. Atherosclerosis 
has been identified using computed tomography in ancient Egyptian, Peruvian, and Native 
American mummies with the Egyptian Princess Ahmose-Meryet-Amon who lived around 1580–1550 
B.C. as the earliest human known to have had coronary artery disease [5,6]. These findings led to the 
question “Might the chronic inflammatory load of ancient times secondary to infection have resulted 
in atherosclerosis?” [5]. The scientific basis of inflammation in atherosclerosis also has a long history. 
The influential European pathologists of the 19th century, Rudolf Virchow and Carl von Rokitansky, 
described inflammatory changes in atherosclerosis, with Virchow supporting the primary role of 
inflammation while von Rokitansky argued that incorporated mural thrombosis was the key 
pathogenic process in atherosclerosis [7]; both mechanisms are incorporated in current concepts of 
the development of atherosclerosis [8]. Insights provided by molecular and cellular biology into the 
complexity of atherosclerosis have given a better idea of the mechanisms that link risk factors such 
as low-density lipoproteins (LDL), hypertension, cigarette smoking, diabetes, and inflammation to 
the clinical disease [9]. 
What is the role of cholesterol in cardiovascular health and disease? As noted by Tsoupras and 
co-authors [1], cholesterol is essential for the normal function of cells including the structural makeup 
and fluidity of cell membranes, signal transduction, intracellular transport, nerve conduction, 
signaling pathways through lipid rafts and caveolae, and, as the precursor for vitamin D, steroid 
hormones, and bile salts. Most of the cholesterol in humans comes from endogenous production, 
supporting the finding by Ancel Keys and co-workers that changing dietary cholesterol in humans 
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produced minor effects on serum cholesterol concentrations [10]. As lipid-soluble compounds, 
cholesterol and triglycerides are transported in lipoproteins that are necessary for absorption of 
dietary lipids from the small intestine, transport of lipids to peripheral tissues, and transport of lipids 
back to the liver and intestine. LDL that transport most of the cholesterol are considered pro-
atherogenic. The connection between cholesterol and atherogenesis was first reported in 1913 by 
Anitschkow and Chalatow in rabbits fed egg yolk [11]. But do dietary cholesterol intakes and serum 
cholesterol concentrations relate to human atherosclerosis? In 1958, Ancel Keys and his team started 
the Seven Countries Study (SCS) which reported marked differences in rates of coronary heart disease 
events and deaths among cohorts and strong associations of average dietary features and blood 
cholesterol concentrations with those rates [12,13]. The controversies from these conclusions are on-
going [14]. Further, the role of dietary fat intakes on cardiovascular disease continues to be argued. 
As a recent example, the Prospective Urban Rural Epidemiology (PURE) study results from 135,335 
subjects over five continents that intake of total fat and individual types of fat was unrelated to 
cardiovascular disease or mortality [15] have been labeled as “misleading” [16]. 
If cholesterol is important in cardiovascular disease, then selective inhibition by the statins of 
HMG-CoA reductase, a rate-limiting step in endogenous cholesterol synthesis, should decrease 
cardiovascular risk. This result has been found in many, but not all, studies. It is now 25 years since 
the publication of the Scandinavian Simvastatin Survival Study (4S) showing that simvastatin 
reduced LDL-cholesterol by 35% with a relative risk of death of 0.70 with 5-year treatment in 4,444 
subjects with angina pectoris or previous myocardial infarction and serum cholesterol concentrations 
of 5.5 to 8 mmol/L [17]. Statin therapy is recommended for primary prevention of stroke with each 
decrease of 1 mmol/L in serum cholesterol concentrations equating to a reduction in relative risk by 
21% [18]. Statin therapy reduced the risk of heart failure in patients with cardiovascular risk factors 
but without heart failure; however, statins did not reduce rates of cardiovascular death in patients 
with heart failure [19]. In contrast, Cochrane meta-analyses of cholesterol lowering with statins in 
peripheral arterial disease of the lower extremities in acute coronary syndromes reported no benefit 
[20,21]. Similarly, the lack of an association between LDL-cholesterol and mortality in the elderly has 
been reported through systematic review [22]. Importantly, statins produce a range of pleiotropic 
effects in addition to inhibition of cholesterol synthesis, especially to reduce inflammatory markers 
such as C-reactive protein, which may be important in reducing the formation of atherosclerotic 
plaque [23]. However, statins do not completely prevent atherosclerotic vascular disease. If 
atherosclerosis is a complex inflammatory disorder, then anti-inflammatory therapy on top of intense 
lipid-lowering treatment should lower the risk of acute cardiovascular events. This has now been 
proved with the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial 
with targeted inhibition of interleukin (IL)-1β with canakinumab [24]. Further, the residual risk after 
canakinumab may be related to the persistence of high concentrations of other inflammatory 
cytokines such as IL-6 and IL-18 [25]. Novel anti-inflammatory compounds are in Phase II and III 
trials for treatment of atherosclerosis [26]. The modulatory role of inflammation is now unambiguous, 
showing that “inflammation provides a pathway that mechanistically links alterations in traditional 
risk factors and modifications in the biology of the artery wall that give rise to atherosclerosis and its 
complications” [27]. 
If inflammation is critical in atherosclerosis, then resolving chronic inflammation could be the 
next approach to decrease atherosclerotic risk. Under normal physiological circumstances, 
inflammation resolves after the clearance of infection or injurious agents; however, in chronic 
conditions, the inflammatory response continues, leading to continuing tissue damage [28]. 
Resolution of inflammation is controlled by specialized proresolving mediators such as lipoxins, 
resolvins, protectins, and maresins [29]. The development of selective compounds that are effective 
in promoting resolution of inflammation will further support the role of inflammation in 
atherosclerosis. 
The formation of inflammatory atherosclerotic lesions follows the accumulation of lipids in the 
vascular wall from the circulation. Plasma cholesterol concentrations may then be a biomarker rather 
than the cause for the development of atherosclerosis, as treatment of inflammation, either prevention 
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or reversal, is the key therapeutic aim. Chronic inflammation has been proposed as a major player in 
the development and progression of other chronic diseases [28,30–32]. Further, targeting chronic 
inflammation has been suggested as an intervention to reduce aging-related complications and 
improving tissue repair [28,33]. 
Chronic inflammation may be managed by lifestyle interventions and dietary modifications to 
restrict progression of tissue damage. Many dietary interventions have been suggested to improve 
outcomes in chronic diseases [34–43]. The main aim of these dietary interventions is to lower 
inflammation in the body. Low prevalence of cardiovascular mortality in the Mediterranean cohorts 
of SCS was correlated to their lifestyle and Mediterranean diet [44,45]. The Prevención con Dieta 
Mediterránea (PREDIMED) trial provided strong evidence for vegetable-based Mediterranean diets 
with increased unsaturated fat and polyphenols in the prevention of cardiovascular disease [46]. The 
PREDIMED trial used the Dietary Inflammatory Index to show an increased risk of cardiovascular 
events with a proinflammatory diet [47]. The Okinawan diet, characterized by low caloric intake; 
high consumption of vegetables (particularly root and green–yellow vegetables), legumes, and fish 
products; low consumption of meat products and dairy products; low fat intake; low-glycemic index 
carbohydrates; high fiber intake; and moderate alcohol consumption, modulates insulin signaling 
and inflammatory pathways [43]. The Okinawan diet has also been suggested to reduce risks for 
aging-associated chronic diseases and to promote longevity [43]. The Nordic diet, which is similar in 
composition to the Mediterranean diet but less researched for health benefits, has shown anti-
inflammatory effects [42]. 
These diets and others such as DASH (Dietary Approaches to Stop Hypertension) and portfolio 
diets have the same aim of reducing systemic inflammation [43]. The reduction in chronic 
inflammation would reduce the tissue damage to prevent disease progression [33]. Improvement in 
tissue status, along with anti-inflammatory effects, would improve overall metabolic health of an 
individual. As an example, the Mediterranean diet decreased hepatic fat content, a risk factor for 
metabolic syndrome, type 2 diabetes, and coronary heart disease [48]. Complete removal of dietary 
meat as in vegetarian diets reduces body mass, improves plasma lipid profile, gut microbiota, and 
insulin sensitivity, and decreases the incidence of cardiovascular disease, stroke, metabolic 
syndrome, arteriosclerosis, diabetes, and cancer. However, the vegetarian diet has been associated 
with development of hyperhomocysteinemia, protein deficiency, anemia, decreased creatinine 
content in muscles, menstrual disruption in women, and increased risk of osteoporosis and bone 
fractures [49–58]. The role of exercise and physical activity in obesity reduction and management 
have been well established [59,60]. With an increased caloric intake, increasing energy expenditure 
through exercise and physical activity will help maintain the weight status [60]. Moreover, a meta-
analysis suggested that engaging in exercise training decreased C-reactive protein regardless of the 
age or sex of the individual [61]. This meta-analysis also concluded that the improvements in C-
reactive protein were greater with a decrease in body mass index or % body fat [61]. Other studies 
have also reported anti-inflammatory benefits of physical activity and exercise [62–66], which would 
certainly help reduce the risk of chronic diseases. 
Tsoupras and colleagues have thoroughly reviewed the role of PAF in controlling inflammation. 
They have clearly listed the roles PAF can play in normal physiological conditions and in 
atherosclerosis and cardiovascular diseases [1]. The question now is whether PAF is the most 
important inflammatory mediator that can be controlled for preventing chronic inflammatory 
diseases. The answer to this question is likely ‘no’ as there are many other regulators of inflammatory 
pathways [66–71]. Thus, identifying and targeting selective inflammatory pathways related to the 
cause and stage of disease development in groups of individuals could provide a more effective 
solution for treating inflammation-induced chronic diseases. 
In conclusion, we agree that the logical way to decrease the inflammation-induced risk of chronic 
diseases such as atherosclerosis is to decrease pro-inflammatory inputs. Using drugs, diets, and 
exercise could provide the anti-inflammatory mechanisms to achieve these targets. However, 
consideration of the wide range of inflammatory mediators in addition to PAF is needed to reduce 
the risk in populations with multifactorial causes for the initiation of inflammation. Finally, while the 
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concept of functional foods allows the testing and eventual use of foods for chronic disease 
prevention and management, attributing the saying to Hippocrates that “Let food be thy medicine 
and medicine be thy food” appears to be a historical, if oft-repeated, misquotation [72]. 
Funding: This research received no external funding. 
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1. Tsoupras, A.; Lordan, R.; Zabetakis, I. Inflammation, not cholesterol, is a cause of chronic disease. Nutrients 
2018, 10, 604. 
2. Ahrens, E.H., Jr. The management of hyperlipidemia: Whether, rather than how. Ann. Intern. Med. 1976, 85, 
87–93. 
3. Steinberg, D. Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the 
cholesterol controversy, part V: The discovery of the statins and the end of the controversy. J. Lipid Res. 
2006, 47, 1339–1351. 
4. Ravnskov, U.; de Lorgeril, M.; Diamond, D.M.; Hama, R.; Hamazaki, T.; Hammarskjold, B.; Hynes, N.; 
Kendrick, M.; Langsjoen, P.H.; Mascitelli, L.; et al. LDL-C does not cause cardiovascular disease: A 
comprehensive review of the current literature. Expert Rev. Clin. Pharmacol. 2018, 11, 959–970. 
5. Thomas, G.S.; Wann, L.S.; Allam, A.H.; Thompson, R.C.; Michalik, D.E.; Sutherland, M.L.; Sutherland, J.D.; 
Lombardi, G.P.; Watson, L.; Cox, S.L.; et al. Why did ancient people have atherosclerosis?: From autopsies 
to computed tomography to potential causes. Glob. Heart 2014, 9, 229–237. 
6. Allam, A.H.; Thompson, R.C.; Wann, L.S.; Miyamoto, M.I.; Nur El-Din Ael, H.; El-Maksoud, G.A.; Al-
Tohamy Soliman, M.; Badr, I.; El-Rahman Amer, H.A.; Sutherland, M.L.; et al. Atherosclerosis in ancient 
Egyptian mummies: The Horus study. JACC Cardiovasc. Imaging 2011, 4, 315–327. 
7. Mayerl, C.; Lukasser, M.; Sedivy, R.; Niederegger, H.; Seiler, R.; Wick, G. Atherosclerosis research from 
past to present—On the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf 
Virchow. Virchows Arch. 2006, 449, 96–103. 
8. Libby, P.; Hansson, G.K. From focal lipid storage to systemic inflammation: JACC review topic of the week. 
J. Am. Coll. Cardiol. 2019, 74, 1594–1607. 
9. Libby, P.; Buring, J.E.; Badimon, L.; Hansson, G.K.; Deanfield, J.; Bittencourt, M.S.; Tokgozoglu, L.; Lewis, 
E.F. Atherosclerosis. Nat. Rev. Dis. Primers 2019, 5, 56. 
10. Keys, A.; Anderson, J.T.; Grande, F. Serum cholesterol response to changes in the diet: II. The effect of 
cholesterol in the diet. Metabolism 1965, 14, 759–765. 
11. Anitschkow, N.; Chalatow, S. Classics in arteriosclerosis research: On experimental cholesterin steatosis 
and its significance in the origin of some pathological processes by N. Anitschkow and S. Chalatow, 
translated by Mary Z. Pelias, 1913. Arteriosclerosis 1983, 3, 178–182. 
12. Keys, A.; Menotti, A.; Karvonen, M.J.; Aravanis, C.; Blackburn, H.; Buzina, R.; Djordjevic, B.S.; Dontas, A.S.; 
Fidanza, F.; Keys, M.H.; et al. The diet and 15-year death rate in the Seven Countries Study. Am. J. Epidemiol. 
1986, 124, 903–915. 
13. Blackburn, H. Invited commentary: 30-year perspective on the Seven Countries Study. Am. J. Epidemiol. 
2017, 185, 1143–1147. 
14. Pett, K.D.; Willett, W.C.; Vartiainen, E.; Katz, D.L. The Seven Countries Study. Eur. Heart J. 2017, 38, 3119–
3121. 
15. Dehghan, M.; Mente, A.; Zhang, X.; Swaminathan, S.; Li, W.; Mohan, V.; Iqbal, R.; Kumar, R.; Wentzel-
Viljoen, E.; Rosengren, A.; et al. Associations of fats and carbohydrate intake with cardiovascular disease 
and mortality in 18 countries from five continents (PURE): A prospective cohort study. Lancet 2017, 390, 
2050–2062. 
16. The Nutrition Source. PURE Study Makes Headlines, but the Conclusions are Misleading. Available online: 
https://www.hsph.harvard.edu/nutritionsource/2017/09/08/pure-study-makes-headlines-but-the-
conclusions-are-misleading/ (accessed on 20 September 2019). 
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients 
with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344, 1383–
1389. 
Nutrients 2019, 11, 2332 5 of 7 
 
18. Castilla-Guerra, L.; Del Carmen Fernandez-Moreno, M.; Colmenero-Camacho, M.A. Statins in stroke 
prevention: Present and future. Curr. Pharm. Des. 2016, 22, 4638–4644. 
19. Lee, M.M.Y.; Sattar, N.; McMurray, J.J.V.; Packard, C.J. Statins in the prevention and treatment of heart 
failure: A review of the evidence. Curr. Atheroscler. Rep. 2019, 21, 41. 
20. Aung, P.P.; Maxwell, H.G.; Jepson, R.G.; Price, J.F.; Leng, G.C. Lipid-lowering for peripheral arterial disease 
of the lower limb. Cochrane Database Syst. Rev. 2007, CD000123, doi:10.1002/14651858.CD000123.pub2. 
21. Vale, N.; Nordmann, A.J.; Schwartz, G.G.; de Lemos, J.; Colivicchi, F.; den Hartog, F.; Ostadal, P.; Macin, 
S.M.; Liem, A.H.; Mills, E.; et al. Statins for acute coronary syndrome. Cochrane Database Syst. Rev. 2014, 
CD006870, doi:10.1002/14651858.CD006870.pub3. 
22. Ravnskov, U.; Diamond, D.M.; Hama, R.; Hamazaki, T.; Hammarskjöld, B.; Hynes, N.; Kendrick, M.; 
Langsjoen, P.H.; Malhotra, A.; Mascitelli, L.; et al. Lack of an association or an inverse association between 
low-density-lipoprotein cholesterol and mortality in the elderly: A systematic review. BMJ Open 2016, 6, 
e010401. 
23. Diamantis, E.; Kyriakos, G.; Quiles-Sanchez, L.V.; Farmaki, P.; Troupis, T. The anti-inflammatory effects of 
statins on coronary artery disease: An updated review of the literature. Curr. Cardiol. Rev. 2017, 13, 209–
216. 
24. Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, 
J.; Koenig, W.; Anker, S.D.; et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. 
N. Engl. J. Med. 2017, 377, 1119–1131. 
25. Ridker, P.M.; MacFadyen, J.G.; Thuren, T.; Libby, P. Residual inflammatory risk associated with 
interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: Further 
rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis. 
Eur. Heart J. 2019, doi:10.1093/eurheartj/ehz1542. 
26. Bertrand, M.J.; Tardif, J.C. Inflammation and beyond: New directions and emerging drugs for treating 
atherosclerosis. Expert Opin. Emerg. Drugs 2017, 22, 1–26. 
27. Libby, P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2045–2051. 
28. Zhong, J.; Shi, G. Editorial: Regulation of inflammation in chronic disease. Front. Immunol. 2019, 10, 737. 
29. Back, M.; Yurdagul, A., Jr.; Tabas, I.; Oorni, K.; Kovanen, P.T. Inflammation and its resolution in 
atherosclerosis: Mediators and therapeutic opportunities. Nat. Rev. Cardiol. 2019, 16, 389–406. 
30. Liu, C.H.; Abrams, N.D.; Carrick, D.M.; Chander, P.; Dwyer, J.; Hamlet, M.R.J.; Macchiarini, F.; PrabhuDas, 
M.; Shen, G.L.; Tandon, P.; et al. Biomarkers of chronic inflammation in disease development and 
prevention: Challenges and opportunities. Nat. Immunol. 2017, 18, 1175–1180. 
31. Fougere, B.; Boulanger, E.; Nourhashemi, F.; Guyonnet, S.; Cesari, M. Chronic inflammation: Accelerator 
of biological aging. J. Gerontol. A Biol. Sci. Med. Sci. 2017, 72, 1218–1225. 
32. Hunter, P. The inflammation theory of disease. The growing realization that chronic inflammation is crucial 
in many diseases opens new avenues for treatment. EMBO Rep. 2012, 13, 968–970. 
33. Neves, J.; Sousa-Victor, P. Regulation of inflammation as an anti-aging intervention. FEBS J. 2019, 
doi:10.1111/febs.15061. 
34. Pasanisi, P.; Gariboldi, M.; Verderio, P.; Signoroni, S.; Mancini, A.; Rivoltini, L.; Milione, M.; Masci, E.; 
Ciniselli, C.M.; Bruno, E.; et al. A pilot low-inflammatory dietary intervention to reduce inflammation and 
improve quality of life in patients with familial adenomatous polyposis: Protocol description and 
preliminary results. Integr. Cancer Ther. 2019, 18, 1534735419846400. 
35. Rees, K.; Takeda, A.; Martin, N.; Ellis, L.; Wijesekara, D.; Vepa, A.; Das, A.; Hartley, L.; Stranges, S. 
Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Cochrane 
Database Syst. Rev. 2019, CD009825, doi:10.1002/14651858.CD009825.pub3. 
36. Hartley, L.; May, M.D.; Loveman, E.; Colquitt, J.L.; Rees, K. Dietary fibre for the primary prevention of 
cardiovascular disease. Cochrane Database Syst. Rev. 2016, CD011472, doi:10.1002/14651858.CD011472.pub2. 
37. Rees, K.; Hartley, L.; Flowers, N.; Clarke, A.; Hooper, L.; Thorogood, M.; Stranges, S. ‘Mediterranean’ 
dietary pattern for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 2013, 
CD009825, doi:10.1002/14651858.CD009825.pub2.  
38. Limketkai, B.N.; Iheozor-Ejiofor, Z.; Gjuladin-Hellon, T.; Parian, A.; Matarese, L.E.; Bracewell, K.; 
MacDonald, J.K.; Gordon, M.; Mullin, G.E. Dietary interventions for induction and maintenance of 
remission in inflammatory bowel disease. Cochrane Database Syst. Rev. 2019, CD012839, 
doi:10.1002/14651858.CD012839.pub2. 
Nutrients 2019, 11, 2332 6 of 7 
 
39. Calder, P.C. Omega-3 fatty acids and inflammatory processes. Nutrients 2010, 2, 355–374. 
40. Layé, S.; Nadjar, A.; Joffre, C.; Bazinet, R.P. Anti-inflammatory effects of omega-3 fatty acids in the brain: 
Physiological mechanisms and relevance to pharmacology. Pharmacol. Rev. 2018, 70, 12–38. 
41. Freitas, R.D.S.; Campos, M.M. Protective effects of omega-3 fatty acids in cancer-related complications. 
Nutrients 2019, 11, 945. 
42. Lankinen, M.; Uusitupa, M.; Schwab, U. Nordic diet and inflammation—A review of observational and 
intervention studies. Nutrients 2019, 11, 1369. 
43. Willcox, D.C.; Scapagnini, G.; Willcox, B.J. Healthy aging diets other than the Mediterranean: A focus on 
the Okinawan diet. Mech. Ageing Dev. 2014, 136–137, 148–162. 
44. Pitsavos, C.; Panagiotakos, D.B.; Menotti, A.; Chrysohoou, C.; Skoumas, J.; Stefanadis, C.; Dontas, A.; 
Toutouzas, P. Forty-year follow-up of coronary heart disease mortality and its predictors: The Corfu cohort 
of the Seven Countries Study. Prev. Cardiol. 2003, 6, 155–160. 
45. Papandreou, C.; Tuomilehto, H. Coronary heart disease mortality in relation to dietary, lifestyle and 
biochemical risk factors in the countries of the Seven Countries Study: A secondary dataset analysis. J. Hum. 
Nutr. Diet. 2014, 27, 168–175. 
46. Martinez-Gonzalez, M.A.; Salas-Salvado, J.; Estruch, R.; Corella, D.; Fito, M.; Ros, E. Benefits of the 
Mediterranean diet: Insights from the PREDIMED study. Prog. Cardiovasc. Dis. 2015, 58, 50–60. 
47. Garcia-Arellano, A.; Ramallal, R.; Ruiz-Canela, M.; Salas-Salvado, J.; Corella, D.; Shivappa, N.; Schroder, 
H.; Hebert, J.R.; Ros, E.; Gomez-Garcia, E.; et al. Dietary inflammatory index and incidence of 
cardiovascular disease in the PREDIMED study. Nutrients 2015, 7, 4124–4138. 
48. Gepner, Y.; Shelef, I.; Komy, O.; Cohen, N.; Schwarzfuchs, D.; Bril, N.; Rein, M.; Serfaty, D.; Kenigsbuch, S.; 
Zelicha, H.; et al. The beneficial effects of Mediterranean diet over low-fat diet may be mediated by 
decreasing hepatic fat content. J. Hepatol. 2019, 71, 379–388. 
49. Pilis, W.; Stec, K.; Zych, M.; Pilis, A. Health benefits and risk associated with adopting a vegetarian diet. 
Rocz. Panstw. Zakl. Hig. 2014, 65, 9–14. 
50. Medawar, E.; Huhn, S.; Villringer, A.; Veronica Witte, A. The effects of plant-based diets on the body and 
the brain: A systematic review. Transl. Psychiatry 2019, 9, 226. 
51. Tomova, A.; Bukovsky, I.; Rembert, E.; Yonas, W.; Alwarith, J.; Barnard, N.D.; Kahleova, H. The effects of 
vegetarian and vegan diets on gut microbiota. Front. Nutr. 2019, 6, 47. 
52. Veronese, N.; Reginster, J.Y. The effects of calorie restriction, intermittent fasting and vegetarian diets on 
bone health. Aging Clin. Exp. Res. 2019, 31, 753–758. 
53. Segovia-Siapco, G.; Sabate, J. Health and sustainability outcomes of vegetarian dietary patterns: A revisit 
of the EPIC-Oxford and the Adventist Health Study-2 cohorts. Eur. J. Clin. Nutr. 2019, 72, 60–70. 
54. Utami, D.B.; Findyartini, A. Plant-based diet for HbA1c reduction in type 2 diabetes mellitus: An evidence-
based case report. Acta Med. Indones. 2018, 50, 260–267. 
55. Gluba-Brzozka, A.; Franczyk, B.; Rysz, J. Vegetarian diet in chronic kidney disease—A friend or foe. 
Nutrients 2017, 9, 374. 
56. Kahleova, H.; Levin, S.; Barnard, N.D. Vegetarian dietary patterns and cardiovascular disease. Prog. 
Cardiovasc. Dis. 2018, 61, 54–61. 
57. Satija, A.; Hu, F.B. Plant-based diets and cardiovascular health. Trends Cardiovasc. Med. 2018, 28, 437–441. 
58. Lee, Y.; Park, K. Adherence to a vegetarian diet and diabetes risk: A systematic review and meta-analysis 
of observational studies. Nutrients 2017, 9, 603. 
59. Chin, S.H.; Kahathuduwa, C.N.; Binks, M. Physical activity and obesity: What we know and what we need 
to know. Obes. Rev. 2016, 17, 1226–1244. 
60. Wiklund, P. The role of physical activity and exercise in obesity and weight management: Time for critical 
appraisal. J. Sport Health Sci. 2016, 5, 151–154. 
61. Fedewa, M.V.; Hathaway, E.D.; Ward-Ritacco, C.L. Effect of exercise training on C-reactive protein: A 
systematic review and meta-analysis of randomised and non-randomised controlled trials. Br. J. Sports Med. 
2017, 51, 670–676. 
62. Ertek, S.; Cicero, A. Impact of physical activity on inflammation: Effects on cardiovascular disease risk and 
other inflammatory conditions. Arch. Med. Sci. 2012, 8, 794–804. 
63. Beavers, K.M.; Brinkley, T.E.; Nicklas, B.J. Effect of exercise training on chronic inflammation. Clin. Chim. 
Acta 2010, 411, 785–793. 
Nutrients 2019, 11, 2332 7 of 7 
 
64. Frith, E.; Loprinzi, P.D. Physical activity, muscle-strengthening activities, and systemic inflammation 
among retinopathy patients. Diabetes Spectr. 2019, 32, 16–20. 
65. Woods, J.A.; Wilund, K.R.; Martin, S.A.; Kistler, B.M. Exercise, inflammation and aging. Aging Dis. 2012, 3, 
130–140. 
66. Suzuki, K. Chronic inflammation as an immunological abnormality and effectiveness of exercise. 
Biomolecules 2019, 9, 223. 
67. Chen, L.; Deng, H.; Cui, H.; Fang, J.; Zuo, Z.; Deng, J.; Li, Y.; Wang, X.; Zhao, L. Inflammatory responses 
and inflammation-associated diseases in organs. Oncotarget 2017, 9, 7204–7218. 
68. Du, C.; Bhatia, M.; Tang, S.C.W.; Zhang, M.; Steiner, T. Mediators of inflammation: Inflammation in cancer, 
chronic diseases, and wound healing. Mediators Inflamm. 2015, 2015, 570653. 
69. Abdulkhaleq, L.A.; Assi, M.A.; Abdullah, R.; Zamri-Saad, M.; Taufiq-Yap, Y.H.; Hezmee, M.N.M. The 
crucial roles of inflammatory mediators in inflammation: A review. Vet. World 2018, 11, 627–635. 
70. Schett, G.; Neurath, M.F. Resolution of chronic inflammatory disease: Universal and tissue-specific 
concepts. Nat. Commun. 2018, 9, 3261. 
71. Libby, P. Inflammatory mechanisms: The molecular basis of inflammation and disease. Nutr. Rev. 2007, 65, 
S140–S146. 
72. Cardenas, D. Let not thy food be confused with thy medicine: The Hippocratic misquotation. e-SPEN J. 
2013, 8, e260–e262. 
 
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
